The University of Southampton
University of Southampton Institutional Repository

The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks

van Staa, Tjeerd-Peter, Kanis, John A., Geusens, Piet, Boonen, Annelies, Leufkens, Hubert G.M. and Cooper, Cyrus (2007) The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks Value in Health, 10, (5), pp. 348-357. (doi:10.1111/j.1524-4733.2007.00188.x).

Record type: Article


OBJECTIVES: Cost-effectiveness analyses are routinely based on data from group averages, restricting its generalizibility to those with below- or above-average risk. A pharmaco-economic model that used individualized risks for fractures was developed in order to take into account patient heterogeneity. METHODS: Data were obtained from The Health Improvement Network research database of general practitioners, comprising a UK general population of women aged more than 50 years (N = 330,000). Mortality and hip, vertebral, and other osteoporotic fracture risks for each individual were estimated by age, body mass index (BMI), smoking, and other clinical risk factors. Estimates on costs, EuroQol (EQ-5D) utilities, and treatment efficacy were obtained from a UK national report (the National Institute for Clinical Excellence) and outcomes were simulated over a 10-year period. RESULTS: It was found that the cost per quality-adjusted life-year (QALY) gained was lower in elderly women and in women with fracture history. There was a large variability in the cost-effectiveness with baseline fracture risk and with clinical risk factors. Patients with low BMI (or=26). Using a cost-acceptability ratio of 30k pounds per QALY gained, bisphosphonate treatment became cost-effective for patients with a 5-year risk of 9.3% (95% confidence interval [CI] 8.0-10.5%) for osteoporotic fractures and of 2.1% (95% CI 1.5-2.7%) for hip fractures. Including bone mineral density in the risk assessment, the cost per QALY gained was 35k pounds in women at age 60 with a fracture history and a T-score of -2.5 (at age 80, this was 3k pounds). CONCLUSION: A pharmacoeconomic model based on individual long-term risks of fracture improves the selection of postmenopausal women for cost-effective treatment with bisphosphonates.

Full text not available from this repository.

More information

Published date: September 2007
Keywords: cost-effectiveness, fracture, osteoporosis, postmenopausal women, risedronate


Local EPrints ID: 61578
ISSN: 1098-3015
PURE UUID: d616574b-e63b-4ed3-9e46-83ab95df110f
ORCID for Cyrus Cooper: ORCID iD

Catalogue record

Date deposited: 07 Oct 2008
Last modified: 17 Jul 2017 14:21

Export record



Author: Tjeerd-Peter van Staa
Author: John A. Kanis
Author: Piet Geusens
Author: Annelies Boonen
Author: Hubert G.M. Leufkens
Author: Cyrus Cooper ORCID iD

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.